Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | FBP1 | P09467 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 3/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12410295 | 0.86 | ADORA2A (0.54) | ADORA2AKDM4EFBP1GSK3BGAA | |
| SCHEMBL12954646 | 0.83 | ADORA2A (0.64) | ADORA2AKDM4EFBP1GSK3BGAA | |
| SCHEMBL13312245 | 0.78 | ADORA2A (0.70) | ADORA2AKDM4EFBP1GSK3BGAA | |
| SCHEMBL27633480 | 0.77 | ADORA2A (0.74) | ADORA2AKDM4EFBP1GSK3BGAA | |
| SCHEMBL287658 | 0.77 | ADORA2A (0.74) | ADORA2AKDM4EFBP1GSK3BGAA | |
| SCHEMBL1969272 | 0.77 | ADORA2A (0.64) | ADORA2AKDM4EFBP1GSK3BGAA | |
| SCHEMBL31050965 | 0.75 | FPR2 (0.48) | KDM4EGAAMEN1KMT2AFPR2 | |
| SCHEMBL9586590 | 0.75 | ADORA2A (0.57) | ADORA2AKDM4EFBP1GSK3BGAA | |
| SCHEMBL6372051 | 0.75 | ADORA2A (0.60) | ADORA2AKDM4EFBP1GSK3BGAA | |
| SCHEMBL631985 | 0.74 | ADORA2A (0.70) | ADORA2AKDM4EFBP1GSK3BGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | ADORA2A 1643/4885KDM4E 3968/4885FBP1 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.